The question is, where is the financing, how much is it? This is in the 10Q
The FDA has authorized its use in 17 different indications, and we had already completed our tests within the VA and gained acceptance. Now, some of the major metropolitan VA centers are still closed to us, but many have reopened. We received an exclusive investment into the restart of revenues activities this week. The use of funds will be used to:
• Convert our existing bulk inventory of Excellagen Wound Conforming Gel Matrix into final fill finish and will be shipping product to AvMedical from our partners in England, BSM. We have enough existing bulk inventory to create approximately 25,000 syringes with 70% converted into our .08 cc syringes and 30% into our 3.0 cc syringes for larger wounds. This process is expected to take 60-90 days to have inventory in place to sale. We believe these runs will support our sales forecast up to approximately $30 million.
• We believe our forecast for this slimmed down focus on just VA will yield, at the end of month 12, an annualized run rate of approximately $10,000,000 while achieving a positive EBITDA in Month 6 of this rollout and an EBITDA projected north of 70%. Years 2 and 3 is forecasted to have $39 million and $92 million of revenue, respectfully, with EBITDA forecasted at $32 million and $65 million, respectfully.
What about the financing from China:
As of April 30, 2021, Generex, has received approximately 4,500,000, net of taxes, from the COVID Agreement in cash to pursue the commercialization of the Vaccine.
Where is the rest of this?
And this:
Similar agreements for RPM have subsequently been signed on May 6, 2021 and May 10, 2021 for Florida Health Care Associates, of Boynton Beach, Fl, and Westside Medical and Cardiology, of Westlake, Ohio. Numerous other clinics in other states are in discussion phase to sign up as well. The company has received its first funds to begin operations and plans its first kick off during the Month of May 2021 in the three signed clinics
These are the things we need to know what information on as well as the IPO. Instead, all we have is silence.
The FDA has authorized its use in 17 different indications, and we had already completed our tests within the VA and gained acceptance. Now, some of the major metropolitan VA centers are still closed to us, but many have reopened. We received an exclusive investment into the restart of revenues activities this week. The use of funds will be used to:
• Convert our existing bulk inventory of Excellagen Wound Conforming Gel Matrix into final fill finish and will be shipping product to AvMedical from our partners in England, BSM. We have enough existing bulk inventory to create approximately 25,000 syringes with 70% converted into our .08 cc syringes and 30% into our 3.0 cc syringes for larger wounds. This process is expected to take 60-90 days to have inventory in place to sale. We believe these runs will support our sales forecast up to approximately $30 million.
• We believe our forecast for this slimmed down focus on just VA will yield, at the end of month 12, an annualized run rate of approximately $10,000,000 while achieving a positive EBITDA in Month 6 of this rollout and an EBITDA projected north of 70%. Years 2 and 3 is forecasted to have $39 million and $92 million of revenue, respectfully, with EBITDA forecasted at $32 million and $65 million, respectfully.
What about the financing from China:
As of April 30, 2021, Generex, has received approximately 4,500,000, net of taxes, from the COVID Agreement in cash to pursue the commercialization of the Vaccine.
Where is the rest of this?
And this:
Similar agreements for RPM have subsequently been signed on May 6, 2021 and May 10, 2021 for Florida Health Care Associates, of Boynton Beach, Fl, and Westside Medical and Cardiology, of Westlake, Ohio. Numerous other clinics in other states are in discussion phase to sign up as well. The company has received its first funds to begin operations and plans its first kick off during the Month of May 2021 in the three signed clinics
These are the things we need to know what information on as well as the IPO. Instead, all we have is silence.
